James E. Shields

Director/Board Member at Allos Therapeutics, Inc.

72 year

Health Technology

Consumer Services

Profile

James E.
Shields is currently a Director at Allos Therapeutics, Inc. Previously, he was the Chief Commercial Officer & Senior Vice President at Spectrum Pharmaceuticals, Inc. He received his undergraduate degree from the University of Kentucky.

James E. Shields active positions

Companies	Position	Start
Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	Director/Board Member	2012-09-04

All active positions of James E. Shields

Former positions of James E. Shields

Companies	Position	End
SPECTRUM PHARMACEUTICALS, INC.	Corporate Officer/Principal	2012-10-28

See the detail of James E. Shields's experience

Training of James E. Shields

University of Kentucky

Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of James E. Shields's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
SPECTRUM PHARMACEUTICALS, INC.	Health Technology

Private companies	1
Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	Health Technology